N4 PHARMA PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.75 GBX | -6.25% |
|
-6.25% | -11.76% |
| Apr. 25 | N4 Pharma strikes partnership deal for intracellular delivery | AN |
| Apr. 23 | N4 Pharma loss widens but "great optimism" remains | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | 1.95K 2.44K | Capitalization | 2.28M 2.85M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -1.25M | Net income 2023 | -1M -1.25M | EV / Sales 2022 | - |
| Net cash position 2022 | 1.92M 2.4M | Net cash position 2023 | 1.03M 1.28M | EV / Sales 2023 | 644 x |
| P/E ratio 2022 |
-3.35
x | P/E ratio 2023 |
-1.63
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 77.72% |
More Fundamentals
* Assessed data
More news
Latest transcript on N4 Pharma Plc
More press releases
| 1 day | -6.25% | ||
| 1 week | -6.25% | ||
| Current month | -6.25% | ||
| 1 month | +3.45% | ||
| 6 months | -14.29% | ||
| Current year | -11.76% |
1 week
0.75
0.85
1 month
0.700.95
Current year
0.601.50
1 year
0.602.16
3 years
0.6010.43
5 years
0.6016.00
10 years
0.6035.70
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 59 | 13-12-31 | |
David Templeton
CTO | Chief Tech/Sci/R&D Officer | - | 17-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 46 | 20-07-13 | |
| Founder | 59 | 13-12-31 | |
Chris Britten
CHM | Chairman | - | 19-05-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 0.75 | -6.25% | 95 549 |
| 24-05-07 | 0.8 | 0.00% | 72,162 |
| 24-05-03 | 0.8 | 0.00% | 198,696 |
| 24-05-02 | 0.8 | 0.00% | 24,007 |
| 24-05-01 | 0.8 | 0.00% | 150,728 |
Delayed Quote London S.E., May 08, 2024 at 05:54 am EDT
More quotes
N4 Pharma Plc is a United Kingdom-based pre-clinical stage specialist pharmaceutical company. The Company is engaged in developing Nuvec, which is a novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. It is also engaged in producing LipTide, which is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells. The peptide binds payload and targets specific cells while the lipid allows for efficient endosomal release into the cell. The Company's subsidiary includes N4 Pharma UK Limited and Nanogenics Limited.
Sector
Pharmaceuticals
Calendar
2024-05-23
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -11.76% | 2.7M | |
| +33.43% | 700B | |
| +27.39% | 569B | |
| -5.12% | 358B | |
| +19.59% | 330B | |
| +4.89% | 287B | |
| +15.89% | 236B | |
| +6.72% | 202B | |
| -9.41% | 197B | |
| +4.26% | 161B |
- Stock Market
- Equities
- ONZ Stock